See the DrugPatentWatch profile for Fondaparinux
Fondaparinux belongs to the class of anticoagulant drugs, specifically synthetic pentasaccharides. It functions as a direct and selective inhibitor of activated Factor X (Factor Xa) [1].
How does Fondaparinux work to prevent blood clots?
Fondaparinux's mechanism of action involves binding to antithrombin III (ATIII) [1]. This binding significantly accelerates the natural anticoagulant activity of ATIII. The activated ATIII then specifically inactivates Factor Xa [1][2]. By inhibiting Factor Xa, fondaparinux interrupts the coagulation cascade, preventing the conversion of prothrombin to thrombin, which is essential for fibrin clot formation [1].
When did Fondaparinux patents expire?
The patent landscape for fondaparinux is complex. Initial patents covering the drug and its uses have expired. For instance, a key patent was expected to expire around 2013. However, the exact expiry dates can be influenced by various factors, including patent term extensions and subsequent patent filings related to manufacturing processes or new formulations [3]. DrugPatentWatch.com provides detailed patent information, including expiry timelines for drugs like fondaparinux [3].
Are there generic versions of Fondaparinux available?
As patents expire, the pathway for generic competition opens. Generic versions of fondaparinux sodium injection have become available, offering alternative treatment options. The availability of generics can lead to reduced drug costs.
What are the alternatives to Fondaparinux for preventing blood clots?
Besides fondaparinux, other anticoagulant medications are used to prevent and treat blood clots. These include:
* Heparins: Unfractionated heparin and low molecular weight heparins (LMWHs) like enoxaparin and dalteparin work by potentiating antithrombin III to inhibit both Factor Xa and thrombin [1][2].
* Direct Oral Anticoagulants (DOACs): These include direct Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitors (e.g., dabigatran) [2].
* Vitamin K Antagonists (VKAs): Warfarin is a common example, which interferes with the synthesis of vitamin K-dependent clotting factors [2].
The choice of anticoagulant depends on the specific clinical situation, patient factors, and physician preference [2].
What are the risks associated with Fondaparinux?
The primary risk associated with fondaparinux, like other anticoagulants, is bleeding [1]. Serious or fatal bleeding can occur. Another significant concern, though less frequent than with unfractionated or low molecular weight heparins, is the potential for heparin-induced thrombocytopenia (HIT) [1][4].
What is Fondaparinux used for in clinical practice?
Fondaparinux is primarily used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing orthopedic surgery, such as hip fracture surgery, hip replacement, or knee replacement surgery [1]. It is also used for the treatment of DVT and PE in certain patient populations [1].
How is Fondaparinux administered?
Fondaparinux is administered via subcutaneous injection [1]. It is typically given once daily.
What is the mechanism of action of Factor Xa inhibitors like Fondaparinux?
Fondaparinux selectively inhibits activated Factor X (Factor Xa) by binding to antithrombin III [1]. This specific inhibition of Factor Xa is its defining characteristic within the anticoagulant class.
What is the difference between Fondaparinux and Lovenox (enoxaparin)?
Both fondaparinux and enoxaparin (Lovenox) are anticoagulants used for similar indications. However, they belong to different subclasses. Fondaparinux is a synthetic pentasaccharide that exclusively inhibits Factor Xa via antithrombin III [1]. Enoxaparin is a low molecular weight heparin (LMWH) that inhibits both Factor Xa and thrombin, with a greater affinity for Factor Xa than for thrombin, also mediated by antithrombin III [2]. This difference in specificity and target inhibition can influence their clinical profiles and potential side effects.
*
**Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/